{
    "clinical_study": {
        "@rank": "16627", 
        "acronym": "Quadritherapy", 
        "arm_group": [
            {
                "arm_group_label": "Arm 1 (Standard therpy)", 
                "arm_group_type": "Experimental", 
                "description": "Arm 1 : subject randomized to this arm will be receiving the standard care therapy for 48 weeks:\nReiferon Retard\u00ae 160 \u00b5g /week subcutaneous injection.\nRibavirin in a dose of 13 mg/kg/day orally"
            }, 
            {
                "arm_group_label": "Arm 2 ( Xerovirinc)", 
                "arm_group_type": "Experimental", 
                "description": "Arm 2 :  Subjects randomized to this arm will be receiving the following medications for 48 weeks;\nReiferon Retard\u00ae 160 \u00b5g /week subcutaneous injection\nRibavirin in a dose of 13 mg/kg/day orally\nXerovirinc\u00ae 500mg twice daily orally."
            }, 
            {
                "arm_group_label": "Arm 3 ( Bon one )", 
                "arm_group_type": "Experimental", 
                "description": "Arm 3: Subjects randomized to this arm will be receiving the following medications for 48 weeks:\nBon-One \u00ae  0.5 \u00b5g daily orally\nReiferon Retard\u00ae 160 \u00b5g /week subcutaneous injection\nRibavirin in a dose of 13 mg/kg/day orally\nXerovirinc\u00ae 500mg twice daily orally."
            }
        ], 
        "brief_summary": {
            "textblock": "A single Center, Prospective Phase IV, Open-Label, Controlled, Randomized Trial comparing\n      the efficacy, safety, and tolerability of Quadritherapy regimen (Reiferon Retard\u00ae ,\n      Ribavirin , Nitazoxanide and Alfacalcidol (Bon-One \u00ae  ) versus Triple therapy regimen\n      (Reiferon Retard\u00ae , Ribavirin and  Nitazoxanide) versus the standard of care\n      regimen(Reiferon Retard\u00ae and Ribavirin) in the treatment of Na\u00efve chronic hepatitis C among\n      the Egyptian population. Effectiveness will be evaluated based on Sustained Virological\n      Response (SVR) .\n\n      PRIMARY OBJECTIVE(S): The primary objectives of this trial are as follows:\n\n        -  To compare the efficacy of the three treatment arms in na\u00efve Chronic Hepatitis C Virus\n           (HCV) genotype 4 patients by evaluating the sustained virological response ( SVR) at\n           week 60 ( 3 months after end of treatment period)\n\n        -  Identify optimum treatment protocol for HCV genotype 4 in respect to used combination\n           of medications\n\n        -  Whether adding vitamin D, a potent immunomodulator, could improve viral response.\n\n      STUDY DESIGN: This is a phase IV, single center, open labeled, randomized (1:1:1) controlled\n      study.\n\n      NUMBER OF EVALUABLE SUBJECTS: 300 NUMBER OF CENTER/S: 1 Country:Egypt DURATION OF THE STUDY:\n       94 weeks TREATMENT: randomized 1:1:1 ratio into 3 Arms SUBJECT POPULATION:  male or female\n      subjects assessed by BMI less than 35, between the ages of 20 and 50 years. Subjects have to\n      be diagnosed as Na\u00efve Chronic Hepatitis C genotype 4 patients with compensated liver disease\n      assessed by hematological and biochemical tests.\n\n      - DURATION OF THE STUDY:  94 weeks as follows:\n\n      Estimated Enrollment Duration: 16 weeks Collection of last Case Report Form (CRF) : 2 weeks\n      from Last patient out. Queries Resolution: 4 weeks from Collection of last CRF. Database\n      lock planned date: 2 weeks from Quires resolution. Final Study Report: 8 weeks from Database\n      lock. Estimated duration of subject participation: 62 weeks as follows;\n\n        -  Screening period per subject = 2 weeks\n\n        -  Treatment phase per subject = 48 weeks\n\n        -  Follow-up phase per subject = 12 weeks\n\n      N.B : Each patient will receive medications for Maximum 48 weeks if his/her Polymerase Chain\n      Reaction (PCR) -ve at weeks 12 and 24 , and if his/her PCR +ve at week 12 or week 24 the\n      treatment will be stopped ."
        }, 
        "brief_title": "Trial Comparing the Efficacy, Tolerability and Safety Between Three Arms in Treatment of HCV in Egyptian Population", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Hepatitis c", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis, Chronic", 
                "Hepatitis C", 
                "Hepatitis C, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. The subject signs and dates a written informed consent form (ICF) prior to any\n             study-related activities, including discontinuation of any prohibited medications.\n\n          2. If the subject is male and sexually active, he is eligible to enter and participate\n             in this study if his partner(s) meet the criteria outlined in 2a or if he or his\n             partner(s) are using one of the methods of birth control outlined in 2b. If the\n             subject is female, she is eligible to enter and participate in this study if she\n             meets the following criteria:\n\n               1. Non-childbearing potential (i.e., physiologically incapable of becoming\n                  pregnant, including any female who is postmenopausal; for purposes of this\n                  study, postmenopausal is defined as 1 year without menses); or\n\n               2. Childbearing potential, has a negative serum pregnancy test at screening.\n\n          3. The subject is between the ages of 20 and 50, inclusive at the time of the screening\n             visit.\n\n          4. The subject is an ambulatory outpatient. Ambulatory is defined as not depending\n             exclusively on a wheelchair for mobility. Nursing home subjects may be enrolled\n             provided they are ambulatory. Subjects with spinal cord injuries resulting in\n             paraplegia may not be enrolled.\n\n          5. The subject is or has been diagnosed with Hepatitis C genotype 4.\n\n          6. Subjects are treatment Naive\n\n          7. Male or female subjects with  BMI \u2264  35 .\n\n          8. Compensated liver disease with all the following minimum hematological and\n             biochemical criteria:\n\n               1. Hemoglobin > 12 g/dl for males, >11 g/dl for females.\n\n               2. White blood cell count (WBC) > 3,000 /mm3 - Absolute Neutrophilic count (ANC\n                  above 1000)\n\n               3. Platelets > 80,000/mm3\n\n               4. Prothrombin time less than 4 seconds above the upper limit of normal (ULN).\n\n               5. Serum albumin > 3.5mg/dl\n\n               6. Normal Bilirubin level (except for Gilbert's syndrome where indirect Bilirubin\n                  should be < 3mg/dl)\n\n               7. Histological diagnosis of chronic hepatitis with Fibroscan( fibrosis\n                  assessment).\n\n               8. Normal fasting blood glucose level or within 20% of ULN for non-diabetic\n                  patients. If there is a history of diabetes, hemoglobin A1C <8.5% (as evidence\n                  of good glucose control in recent months).\n\n          9. Serum Creatinine within normal limits.\n\n         10. Thyroid Stimulating Hormone (TSH) within normal limits of testing lab. Patients\n             requiring medications to maintain TSH are eligible if they have fulfilled all other\n             inclusion and exclusion criteria.\n\n         11. Alpha Fetoprotein within normal range obtained during one year prior to entry in the\n             study. Results above the upper limit of normal but less than 100 units require both\n             of the following:\n\n               1. Alpha Fetoprotein obtained within 3 months of entry.\n\n               2. Abdominal Ultrasound within 3 months of entry that is negative for evidence of\n                  hepatocellular carcinoma.\n\n               3. If Alpha Fetoprotein is above 100 units CT scan of the abdomen that is negative\n                  for evidence of hepatocellular carcinoma is required.\n\n         12. Patients must be serum hepatitis B surface antigen (HBsAg) negative.\n\n         13. Negative Antinuclear Antibodies (ANA) or titer of < 1:160\n\n         14. Serum positive for anti-HCV antibodies and HCV-RNA.\n\n         15. Abdominal Ultrasound obtained within one year prior to entry in the study\n\n         16. Electrocardiogram for men aged > 40 years.\n\n         17. Normal urine analysis.\n\n         18. Normal fundus exam.\n\n         19. Serum Schistosoma antibody test, if positive > 1/80, a rectal biopsy is required. If\n             rectal biopsy is positive to living Schistosomal eggs, treatment of Active\n             Schistosomal disease is required one month prior to enrollment.\n\n        Exclusion Criteria:\n\n          1. The subject has been diagnosed with HBV or HCV of any genotype other than genotype 4\n             and /or HIV.\n\n          2. Subjects are older than 50 years or younger than 20 years of age.\n\n          3. Women who are pregnant or breast-feeding.\n\n          4. Suspected hypersensitivity to Interferon or Ribavirin.\n\n          5. Subjects with organ transplant other than corneal or hair transplant.\n\n          6. Any cause of the liver disease based on the patient's history and biopsy other than\n             chronic hepatitis C genotype 4, including but not limited to:\n\n               1. Alpha 1-antitrypsin deficiency.\n\n               2. Wilson's disease.\n\n               3. Liver transplant patients.\n\n               4. Autoimmune hepatitis.\n\n               5. Alcoholic liver disease.\n\n               6. Obesity induced disease.\n\n               7. Drug related liver disease.\n\n               8. Co-infection with Hepatitis B Virus (HBV) or HIV (HBsAg or HIV antibodies\n                  positivity).\n\n               9. Hemochromatosis (iron deposition more than 2+ in liver parenchyma)\n\n              10. Evidence of advanced liver disease such as history or presence of ascitis,\n                  bleeding varices, spontaneous encephalopathy.\n\n          7. In the opinion of the investigator, the subject has a concurrent illness or\n             disability (excluding HCV genotype 4) that may affect the interpretation of clinical\n             efficacy and/or safety data or otherwise contraindicates participation in this\n             clinical study ;\n\n               1. Unstable pulmonary, endocrine & metabolic disorders e.g. poorly controlled\n                  diabetes.\n\n               2. Subjects with hemophilia or any hemoglobinopathy including but not limited to\n                  thalassemia major or minor.\n\n               3. Bone marrow compromise contraindicated for interferon treatment\n\n               4. Central Nervous System (CNS) trauma or active seizures that require medications.\n\n               5. The subject exhibits renal impairment as evidenced by a serum Creatinine higher\n                  than 2.0 mg/dL. Or history of Chronic renal failure\n\n               6. Immunologically mediated diseases (e.g. inflammatory bowel disease, idiopathic\n                  thrombocytopenic purpura, systemic lupus erythromatosis, autoimmune hemolytic\n                  anemia, scleroderma, severe psoriasis, clinical cryoglobulinemia)\n\n               7. Any medical condition requiring or likely to require during course of the study,\n                  chronic systemic administration of steroids.\n\n               8. Patients with clinically significant retinal abnormalities.\n\n               9. The subject has a history of unstable or deteriorating cardiac disease within\n                  the previous 6 months, including, but not limited to, the following:\n\n             i. Myocardial infarction, unstable angina pectoris, coronary artery bypass surgery,\n             or coronary angioplasty ii. Congestive heart failure requiring hospitalization iii.\n             Uncontrolled arrhythmias\n\n          8. The subject has been diagnosed with a major psychiatric disorder (e.g., major\n             depression or psychoses) within the past 2 years that required hospitalization and/or\n             involved an attempted suicide. Subjects diagnosed with a major psychiatric disorder\n             that did not require hospitalization or involve an attempted suicide must have\n             remained on a stable dose of medication for at least 6 months prior to the screening\n             visit.\n\n          9. The subject has a history of alcohol or substance abuse within the past 2 years.\n\n         10. The subject has a positive stool sample for ova or parasite (exception:  the finding\n             of Entamoeba coli is not exclusionary).\n\n         11. The subject has any evidence or treatment of malignancy (other than localized basal\n             cell cancer, squamous cell skin cancer, or cancer in situ that has been resected)\n             within the previous 5 years.\n\n         12. The subject  used an investigational drug or participated in an investigational study\n             within 30 days of screening.\n\n         13. The subject refuses to discontinue one (or more) prohibited medications at least 7\n             days prior to the screening visit.\n\n         14. The subject refuses to maintain a stable dose of one (or more) allowable concurrent\n             medications for at least 30 days prior to the screening visit.\n\n         15. The subject is unable or unwilling to follow directions.\n\n         16. Contraindications to ribavirin and thus combination therapy include marked anemia,\n             renal dysfunction, and coronary artery or cerebrovascular disease, and inability to\n             practice birth control."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "50 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01896609", 
            "org_study_id": "HCV05012012"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Arm 1 (Standard therpy)", 
                    "Arm 2 ( Xerovirinc)", 
                    "Arm 3 ( Bon one )"
                ], 
                "description": "Arm 1,2,3 Reiferon Retard\u00ae 160 \u00b5g /week subcutaneous injection for 48 weeks", 
                "intervention_name": "Reiferon Retard in Arm 1", 
                "intervention_type": "Biological", 
                "other_name": "Pegylated interferon alfa-2a (Reiferon Retard 160 \u00b5g \u00ae)"
            }, 
            {
                "arm_group_label": "Arm 3 ( Bon one )", 
                "description": "Arm 3 , Bon One \u00ae  0.5 \u00b5g daily orally for 48 weeks", 
                "intervention_name": "Bon one in Arm 3", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Arm 2 ( Xerovirinc)", 
                    "Arm 3 ( Bon one )"
                ], 
                "description": "Arm 2,3  Xerovirinc\u00ae 500mg twice daily orally for 48 weeks", 
                "intervention_name": "Xerovirinc in Arm 2", 
                "intervention_type": "Drug", 
                "other_name": "Nitazoxanide"
            }, 
            {
                "arm_group_label": [
                    "Arm 1 (Standard therpy)", 
                    "Arm 2 ( Xerovirinc)", 
                    "Arm 3 ( Bon one )"
                ], 
                "description": "Arm 1,2,3 Ribavirin in a dose of 13 mg/kg/day orally for 48 weeks", 
                "intervention_name": "Ribavirin in Arm 1", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Interferon-alpha", 
                "Interferon Alfa-2a", 
                "Ribavirin", 
                "Peginterferon alfa-2a", 
                "Nitazoxanide"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Chronic hepatitis c", 
            "Egyptian population", 
            "Reiferon Retard", 
            "Ribavirin", 
            "Nitazoxanide", 
            "Bon one"
        ], 
        "lastchanged_date": "July 10, 2013", 
        "location": {
            "contact": {
                "email": "rasha7019@yahoo.com", 
                "last_name": "Rasha Ahmed, MD", 
                "phone": "+201063432400"
            }, 
            "contact_backup": {
                "email": "msameer@minapharm.com", 
                "last_name": "Moustafa Sameer", 
                "phone": "+201006016212"
            }, 
            "facility": {
                "address": {
                    "city": "Cairo", 
                    "country": "Egypt"
                }, 
                "name": "Faculty of Medicine , Cairo University"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Egypt"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Single Center, Prospective Phase IV, Open-Label, Randomized Trial Comparing the Efficacy , Tolerability, and Safety of Quadritherapy Regimen (Reiferon Retard\u00ae + Ribavirin + Nitazoxanide + Alfacalcidol ( Bon-One \u00ae) ) Versus Triple Therapy Regimen (Reiferon Retard\u00ae + Ribavirin + Nitazoxanide) Versus the Standard of Care Regimen(Reiferon Retard\u00ae + Ribavirin) in the Treatment of Na\u00efve Chronic Hepatitis- C Among the Egyptian Population. Effectiveness Will be Evaluated Based on Sustained Viral Response (SVR)", 
        "other_outcome": {
            "description": "Any adverse event will be found during the period of study medications taking will be recorded .", 
            "measure": "Safety outcome", 
            "safety_issue": "Yes", 
            "time_frame": "During the period of study medications taking (up to 48 weeks)"
        }, 
        "overall_official": [
            {
                "affiliation": "Faculty of Medicine , Cairo University", 
                "last_name": "Gamal Esmat, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Faculty of Medicine , Cairo University", 
                "last_name": "Rasha Ahmed, MD", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Egypt: Ministry of Health and Population", 
                "Egypt : Research Ethics Committee , Faculty of Medicine , Cairo University"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Early Virological Response (EVR) achieved by undetected Hepatitis C Virus (HCV) RNA after 12 weeks ( 3 months after start of treatment)", 
            "measure": "Early virological response", 
            "safety_issue": "No", 
            "time_frame": "3 months after start of treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01896609"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Sustained Virological Response ( SVR ) achieved by undetected HCV RNA after 1 year and 12 weeks (3 months after end of treatment) .", 
            "measure": "Sustained Virological Response ( SVR )", 
            "safety_issue": "No", 
            "time_frame": "3 months after end of treatmet ( Week 60)"
        }, 
        "source": "MinaPharm Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "MinaPharm Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}